GlassScriptPhysician profile
Rose J Kenny
NPI 1194975037
$2,207.36
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $640 · 2021: $305.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $450.30 | 2019-2021 | |
| Pfizer INC. | $259.18 | 2019-2021 | |
| Abbvie INC. | $218.49 | 2019-2021 | |
| Amgen INC. | $140.18 | 2019 | |
| Allergan, INC. | $110.98 | 2019-2020 | |
| Lilly USA, LLC | $109.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $99.83 | 2019 | |
| Upsher-Smith Laboratories LLC | $96.44 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $67.12 | 2019 | |
| Indivior INC. | $62.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $62.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.36 | 2019-2021 | |
| Eisai INC. | $55.15 | 2020-2021 | |
| Sanofi Pasteur INC. | $51.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.25 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.43 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $38.79 | 2019 | |
| Daiichi Sankyo INC. | $38.51 | 2021 | |
| Medtronic, INC. | $36.72 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.44 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $24.86 | 2019 | |
| Janssen Biotech, INC. | $22.33 | 2019 | |
| Alfasigma USA, INC. | $21.66 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Kenny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.